HPV vaccine
Conditions
Brief summary
Complete remission of cutaneous warts 7 months after the first injection of the vaccine
Detailed description
Quality of Life will be evaluated with QoL Questionnaire (DLQI) at M0, M2, M6, M7, Pain will be assess using VAS at M0, M2, M6, M7, Functional discomfort for walking and functional disability in hands will be evaluated using the Revised Foot Function index or Cochin hand function scale respectively at M0, M2, M6, M7, Partial remission of cutaneous warts 7 months after the first injection of the vaccine., Number of warts appeared at M2, M6, M7
Interventions
DRUGSODIUM CHLORIDE
DRUGadsorbed)
Sponsors
Assistance Publique Hopitaux De Paris
Eligibility
Sex/Gender
All
Age
0 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission of cutaneous warts 7 months after the first injection of the vaccine | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life will be evaluated with QoL Questionnaire (DLQI) at M0, M2, M6, M7, Pain will be assess using VAS at M0, M2, M6, M7, Functional discomfort for walking and functional disability in hands will be evaluated using the Revised Foot Function index or Cochin hand function scale respectively at M0, M2, M6, M7, Partial remission of cutaneous warts 7 months after the first injection of the vaccine., Number of warts appeared at M2, M6, M7 | — |
Countries
France
Outcome results
None listed